The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abrogation of Anti-HLA Antibodies via Proteasome Inhibition
Abstract
Background.: Current treatments for autoantibody-mediated diseases (i.e., systemic lupus erythematosus) and alloantibodies (in transplant) are minimally effective. Although they deplete naïve B cells, plasmablasts, and transiently reduce antibody concentrations, they are minimally effective against long-lived, antibody-producing plasma cells. In transplantation, plasma cells produce antibodies directed against human leukocyte antigen (HLA) antigens causing poor allograft survival. We report the first clinical experience with a plasma cell depleting therapy, bortezomib, to abrogate anti-HLA antibodies in transplantation (outside of rejection) in an attempt to improve long-term allograft survival. Methods.: Eleven patients with anti-HLA alloantibodies were treated with bortezomib. All patients underwent plasmapheresis to aid in removal of antibodies and to determine the effect of bortezomib. Serial measurements of anti-HLA antibody levels were conducted weekly by single antigen bead on Luminex platform. Results.: Bortezomib treatment elicited substantial reduction in both donor-specific antibody (DSA) and non-DSA levels. Antibodies were directed against DSA in 8 of 11 cases. Mean time to antibody appearance was 2 months posttransplant. Within 22 days (median) from treatment initiation, 9 of 11 patients’ antibody levels dropped to less than 1000 mean fluorescence intensity. Of two patients without successful depletion, all had peak mean fluorescence intensity more than 10,000. At a mean follow-up of approximately 4 months posttreatment, all patients have stable graft function. Minimal transient side effects were noticed with bortezomib in the form of gastrointestinal toxicity, thrombocytopenia, and paresthesias. Conclusions.: Bortezomib therapy effectively abrogates anti-HLA antibodies. Hence, removal of antibodies, by proteasome inhibition, represents a new treatment strategy for transplantation and may have benefit in autoimmune-related disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Chauhan, D., Catley, L., Li, G., Podar, K., Hideshima, T., Velankar, M., Mitsiades, C., Mitsiades, N., Yasui, H., Letai, A., et al. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.10.013 · Cited by 694
Cited by
Proteasome Inhibitors: An Expanding Army Attacking a Unique Target
Kisselev, A. F., van der Linden, W. A., & Overkleeft, H. S. (2012) · Chemistry & Biology · doi:10.1016/j.chembiol.2012.01.003 · Cited by 527
Long-lived autoreactive plasma cells drive persistent autoimmune inflammation
Hiepe, F., Dörner, T., Hauser, A. E., Hoyer, B. F., Mei, H., & Radbruch, A. (2011) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2011.1 · Cited by 389
Colvin, M. M., Cook, J. L., Chang, P., Francis, G., Hsu, D. T., Kiernan, M. S., Kobashigawa, J. A., Lindenfeld, J., Masri, S. C., Miller, D., et al. (2015) · Circulation · doi:10.1161/cir.0000000000000093 · Cited by 376
Report from a consensus conference on antibody-mediated rejection in heart transplantation
Kobashigawa, J., Crespo-Leiro, M. G., Ensminger, S. M., Reichenspurner, H., Angelini, A., Berry, G., Burke, M., Czer, L., Hiemann, N., Kfoury, A. G., et al. (2011) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2010.11.003 · Cited by 368
A Randomized Trial of Bortezomib in Late Antibody-Mediated Kidney Transplant Rejection
Eskandary, F., Regele, H., Baumann, L., Bond, G., Kozakowski, N., Wahrmann, M., Hidalgo, L. G., Haslacher, H., Kaltenecker, C. C., Aretin, M.-B., et al. (2018) · Journal of the American Society of Nephrology · doi:10.1681/asn.2017070818 · Cited by 306
Metadata
- Authors
- Trivedi, H. L., Terasaki, P. I., Feroz, A., Everly, M. J., Vanikar, A. V., Shankar, V., Trivedi, V. B., Kaneku, H., Idica, A. K., Modi, P. R., Khemchandani, S. I., & Dave, S. D.
- Venue
- Transplantation
- Published
- 2009-05-27
- Volume
- 87
- Issue
- 10
- Pages
- 1555-1561
- ISSN
- 0041-1337 (ISSN-L)
- OpenAlex
- W2031809342
- Cited by
- 164
- References
- 1
- FWCI
- 18.77
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.